Tumor marker assessment in the surveillance period may be more of a hindrance than a help.
Dr. Alan P. Lyss highlights two articles that demonstrate the safety of established treatments – nephrectomy and stereotactic ablative body...
Dr. Stephen S. Grubbs, of the American Society of Clinical Oncology, discusses the future of the Oncology Care Model and other options for value-...
Law & Medicine
Health care fraud, waste, and abuse consume some 10% of federal health expenditures.
Dr. Alan P. Lyss reflects on the significance of two studies from ESMO 2019 that show significant survival improvements in NSCLC and breast cancer...
Black women report symptoms less, have more delays in diagnosis, and experience more frequent deviations from guideline-directed diagnostics.
My answers do not always satisfy their questions. Because it’s not a question seeking an informational answer. The truth is, medically and...
A reference guide for the latest drug approvals in hematology and oncology, including biosimilars.
From the Editor
When assessing whether to recommend treatment, it’s tough to know the difference between tricks and treats.
Law & Medicine
The plaintiff will typically be disqualified from offering medical testimony, unless there is “common knowledge.”
USPSTF recommendations on risk assessment, genetic counseling, and genetic testing for BRCA-related cancer
They recommend using screening tools focusing on family history that primary care physicians can utilize to determine who should be referred for...